DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect

Oncology Letters

Volumn 13, Issue 3, 2017, Pages 1569-1574

  Perez Trujillo, Jose J ^a   Garza Morales, Rodolfo ^a   Barron Cantu, Jose A ^a   Figueroa Parra, Gabriel ^a   Garcia Garcia, Aracely ^a   Rodriguez Rocha, Humberto ^a   Garcia Juarez, Jaime ^a   Muñoz Maldonado, Gerardo E ^b   Saucedo Cardenas, Odila ^a,c   Montes De Oca Luna, Roberto ^a   Loera Arias, Maria De Jesus ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CALRETICULIN; DNA VACCINE; GAMMA INTERFERON; GLUTAMIC ACID; HUMAN CALRETICULIN SIGNAL PEPTIDE E6E7M; HUMAN PAPILLOMAVIRUS ANTIGEN; LEUCINE; LYSINE; PROTEIN E6; PROTEIN E7; RABBIT CALRETICULIN E7 PEPTIDE; SIGNAL PEPTIDE; SIGNAL PEPTIDE E6E7M KDEL DNA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; GENE GUN IMMUNIZATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOFLUORESCENCE TEST; LUNG NODULE; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; WESTERN BLOTTING;

EID: 85011824604     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.5635     Document Type: Article

References (36)

1. Tan S, de Vries EG, van der Zee AG and de Jong S: Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 12: 170-184, 2012.
2. de Boer MA, Jordanova ES, van Poelgeest MI, van den Akker BE, van der Burg SH, Kenter GG and Fleuren GJ: Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int J Cancer 121: 2711-2715, 2007.
3. Bukur J, Jasinski S and Seliger B: The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 22: 350-358, 2012.
4. Yewdell JW: Not such a dismal science: The economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 11: 294-297, 2001.
5. Ashrafi GH, Brown DR, Fife KH and Campo MS: Down-regu­lation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 120: 208-211, 2006.
6. Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5: 178-186, 1999.
7. Tatsis N and Ertl HC: Adenoviruses as vaccine vectors. Mol Ther 10: 616-629, 2004.
8. Neefjes J, Jongsma ML, Paul P and Bakke O: Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11: 823-836, 2011.
9. Yang B, Jeang J, Yang A, Wu TC and Hung CF: DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 10: 3153-3164, 2014.
10. Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH and Wu TC: Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22: 3993-4001, 2004.
11. Gomez-Gutierrez JG, Elpek KG, Montes de OcaLuna R, Shirwan H, Sam Zhou H and McMasters KM: Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 56: 997-1007, 2007.
12. Sheng W, Chen C, Dong M, Zhou J, Liu Q, Dong Q and Li F: Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. J Cell Physiol 229: 887-897, 2014.
13. Erić-Nikolić A, Milovanović Z, Sánchez D, Pekáriková A, Džodić R, Matić IZ, Tučková L, Jevrić M, Buta M, Rašković S and Juranić Z: Overexpression of calreticulin in malignant and benign breast tumors: Relationship with humoral immunity. Oncology 82: 48-55, 2012.
14. Loera-Arias MJ, Martínez-Pérez AG, Barrera-Hernández A, Ibarra-Obregón ER, González-Saldívar G, Martínez-Ortega JI, Rosas-Taraco A, Villanueva-Olivo A, Esparza-González SC, Villatoro-Hernandez J, et al: Targeting and retention of HPV16 E7 to the endoplasmic reticulum enhances immune tumour protection. J Cell Mol Med 14: 890-894, 2010.
15. Peng S, Tomson TT, Trimble C, He L, Hung CF and Wu TC: A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13: 257-265, 2006.
16. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, Weiner DB and Sewell D: Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 27: 431-440, 2009.
17. Zhou X, Qian X, Zhao Q, Lu Y and Xiong M: Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model. Biol Pharm Bull 27: 303-307, 2004.
18. Shi W, Bu P, Liu J, Polack A, Fisher S and Qiao L: Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73: 7877-7881, 1999.
19. Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A and Soleimanjahi H: DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice. J Virol Methods 206: 12-18, 2014.
20. Cheung YK, Cheng SC, Sin FW and Xie Y: Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 23: 629-638, 2004.
21. Amine A, Rivera S, Opolon P, Dekkal M, Biard DS, Bouamar H, Louache F, McKay MJ, Bourhis J, Deutsch E and Vozenin-Brotons MC: Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV+ tumor cells. PLoS One 4: e5018, 2009.
22. Del Cid N, Jeffery E, Rizvi SM, Stamper E, Peters LR, Brown WC, Provoda C and Raghavan M: Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J Biol Chem 285: 4520-4535, 2010.
23. Gelebart P, Opas M and Michalak M: Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 37: 260-266, 2005.
24. Murphy-Ullrich JE: The de-adhesive activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? J Clin Invest 107: 785-790, 2001.
25. Goicoechea S, Orr AW, Pallero MA, Eggleton P and Murphy-Ullrich JE: Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J Biol Chem 275: 36358-36368, 2000.
26. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA and Wu TC: Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 11: 1011-1018, 2004.
27. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF and Wu TC: Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78: 8468-8476, 2004.
28. Kang TH, Chung JY, Monie A, Pai SI, Hung CF and Wu TC: Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Gene Ther 17: 531-540, 2010.
29. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M and Wu TC: Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678, 2001.
30. Zamanian M, Veerakumarasivam A, Abdullah S and Rosli R: Calreticulin and cancer. Pathol Oncol Res 19: 149-154, 2013.
31. Chiang WF, Hwang TZ, Hour TC, Wang LH, Chiu CC, Chen HR, Wu YJ, Wang CC, Wang LF, Chien CY, et al: Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol 49: 534-541, 2013.
32. Shi F, Shang L, Pan BQ, Wang XM, Jiang YY, Hao JJ, Zhang Y, Cai Y, Xu X, Zhan QM and Wang MR: Calreticulin promotes migration and invasion of esophageal cancer cells by upregu­lating neuropilin-1 expression via STAT5A. Clin Cancer Res 20: 6153-6162, 2014.
33. Peachman KK, Rao M and Alving CR: Immunization with DNA through the skin. Methods 31: 232-242, 2003.
34. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM and Wu TC: Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncop­rotein. Int J Cancer 78: 41-45, 1998.
35. Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, Hung CF and Wu TC: Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother 62: 1175-1185, 2013.
36. Chen S, Liao C, Lai Y, Fan Y, Lu G, Wang H, Zhang X, Lin MC, Leng S and Kung HF: De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin. Acta Biochim Biophys Sin (Shanghai) 46: 6-14, 2014.